Compare · BSX vs UFPT
BSX vs UFPT
Side-by-side comparison of Boston Scientific Corporation (BSX) and UFP Technologies Inc. (UFPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and UFPT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 30.7x UFPT ($2.36B).
- Over the past year, BSX is down 53.1% and UFPT is up 39.0% - UFPT leads by 92.1 points.
- UFPT has been more active in the news (12 items in the past 4 weeks vs 10 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 7 for UFPT).
- Company
- Boston Scientific Corporation
- UFP Technologies Inc.
- Price
- -
- -
- Market cap
- $72.26B
- $2.36B
- 1M return
- +9.58%
- +22.11%
- 1Y return
- -53.13%
- +38.99%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1993
- News (4w)
- 10
- 12
- Recent ratings
- 25
- 7
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest UFPT
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the 17th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL
- Director Hudson Symeria sold $95,095 worth of shares (298 units at $319.11), decreasing direct ownership by 24% to 927 units (SEC Form 4)
- Director Hudson Symeria sold $625,141 worth of shares (1,926 units at $324.58) and exercised 1,196 shares at a strike of $206.29, decreasing direct ownership by 37% to 1,225 units (SEC Form 4)
- Director Feldmann Cynthia L sold $324,260 worth of shares (1,000 units at $324.26), decreasing direct ownership by 18% to 4,476 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Hassett Joseph John
- Executive Chairman Bailly R Jeffrey sold $4,113,221 worth of shares (13,011 units at $316.13) (SEC Form 4)
- Executive Chairman Bailly R Jeffrey sold $4,997,051 worth of shares (15,695 units at $318.38) (SEC Form 4)
- Vice President Holt Jason sold $348,700 worth of shares (1,100 units at $317.00), decreasing direct ownership by 12% to 7,878 units (SEC Form 4)
- SEC Form 10-Q filed by UFP Technologies Inc.